Cargando…

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakiyama, Emiko, Chinen, Yoshiaki, Tsukamoto, Taku, Takimoto-Shimomura, Tomoko, Kuwahara-Ota, Saeko, Matsumura-Kimoto, Yayoi, Shimura, Yuji, Kobayashi, Tsutomu, Horiike, Shigeo, Kuroda, Junya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152536/ https://www.ncbi.nlm.nih.gov/pubmed/32308443 http://dx.doi.org/10.2147/IDR.S249030

Ejemplares similares

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma
por: Matsumura‐Kimoto, Yayoi, et al.
Publicado: (2020)

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma
por: Fujibayashi, Yuto, et al.
Publicado: (2020)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy
por: Mizuno, Yoshimi, et al.
Publicado: (2018)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
por: Blum, Sabine, et al.
Publicado: (2016)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
por: Sekhri, Rohit, et al.
Publicado: (2021)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
por: Sadjadian, Parvis, et al.
Publicado: (2020)

Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera
por: Swei, Eric C., et al.
Publicado: (2022)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Extranodal marginal zone lymphoma of the uterine cervix with concomitant copy number gains of the MALT1 and BCL2 genes: A case report
por: Takimoto, Tomoko, et al.
Publicado: (2017)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis
por: Koshiishi, Megumi, et al.
Publicado: (2017)

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?
por: Silver, Richard T.
Publicado: (2020)

Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes
por: Cingam, Shashank, et al.
Publicado: (2019)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
por: Kawaji‐Kanayama, Yuka, et al.
Publicado: (2021)

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Gastric Myeloid Sarcoma Mimicking a Scirrhous Gastric Cancer
por: Taminishi-Katsuragawa, Yoko, et al.
Publicado: (2021)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
por: Okamoto, Haruya, et al.
Publicado: (2021)

8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia
por: Chinen, Yoshiaki, et al.
Publicado: (2014)

Treatment rationale and design of a phase II study of narrow-band ultraviolet B phototherapy for cutaneous steroid-refractory acute graft-vs-host disease following allogenic stem-cell transplantation
por: Asai, Jun, et al.
Publicado: (2019)

Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
por: Shimura, Yuji, et al.
Publicado: (2014)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
por: Griesshammer, Martin, et al.
Publicado: (2018)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
por: Masucci, Chiara, et al.
Publicado: (2023)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma
por: Matsumoto, Yosuke, et al.
Publicado: (2021)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_02fdb48obm0cc4a5f16pb4klhc